Navigation Links
Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15%
Date:12/14/2007

FAIRFIELD, N.J., Dec. 14 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. (NYSE: BDY) today announced its launch of Veregen(TM) (sinecatechins) Ointment, 15%, indicated for the topical treatment of external genital (EGW) and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older. Veregen(TM) is the first new prescription treatment for external genital warts in ten years. Bradley licensed the product from MediGene AG (Frankfurt: MDG) and has exclusive marketing rights in the United States.

Veregen(TM) is the first botanical drug approved for prescription use in the United States and is patented through 2017, with additional applications pending which, if approved, would extend patents beyond 2020. The active ingredient in Veregen(TM) is sinecatechins, a proprietary mixture of 8 catechins, the primary phenols found in green tea leaves. The health benefits associated with catechins are attributed in part to their antioxidant properties.

In two Phase III randomized, double-blind, vehicle-controlled studies, Veregen(TM) proved effective in clearing both baseline and newly emerging external genital and perianal warts, with complete clearance in 53.6% of all patients studied who received Veregen(TM) (as compared to 35.3% of those patients receiving vehicle). Veregen(TM) also demonstrated low recurrence rates during these trials. When treated with Veregen(TM), only 6.8% of the patients experienced recurrence. The majority of adverse reactions reported during these studies were mild to moderate skin and application site reactions, and there were no systemic side effects reported.

External genital warts are one of the most common and fastest spreading venereal diseases worldwide. More than 1
'/>"/>

SOURCE Bradley Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... 2 Martek Biosciences Co... intends to release the results of its fourth quar...approximately 4:00 p.m. Eastern Time (ET). Follow...ct a conference call to discuss these results with...the call live via webcast by visiting Martek,s web...
(Date:12/2/2009)...Newswire-USNewswire/ -- Nearly 600 medical researc...rs today convened to explore novel development app...naugural Partnering for Cures meeting. ,, F...lken Institute, convened Partnering for Cures to...turn a scientific discovery into an accessible the...
(Date:12/2/2009)...therlands, December 2 Pepscan Hold...y focusing on protein mimicking,technology for the... that it,has appointed Wim E.M. Mol, Ph.D. as new ...e responsible for all of Pepscans corporate functi...tion of the company. He brings to,Pepscan more tha...
(Date:12/2/2009)..., Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutic... ), a leading pharmaceutical company,specializing ...f branded,generic and proprietary pharmaceuticals ...ve been included in China,s National Drug Reimburs...inistry of Human Resources and Social,Security on ...
Breaking Biology Technology:Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Dutch Biotech Company Pepscan Appoints New CEO 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
...d for Targeting Tumors and Other, Abnormalities w...urgery, PALO ALTO, Calif., Sept. 18 Varian Medic...0(k) clearance for a new,high-definition multileaf...ce for radiosurgery. The new HD120 MLC multileaf ... precise radiosurgical treatments, including inten...
...cals Plc, a,private biopharmaceutical company focu...flammatory drugs, announced today that it has,appo...Chief Executive,Officer. Dr. Mazanet has significa...nagement in the biopharmaceutical industry. Dr. M... public,pharmaceutical companies. From June 1998 t...
...apies today,announced it has developed a novel ser... the treatment of female sexual dysfunction (FSD)....nt inhibitors designed to,regulate neuronal activi...elieves these compounds may have utility in the tr...), a condition that affects a significant,percenta...
Other Biology Technology:Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery 2Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery 3Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer 2Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD) 2Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD) 3
(Date:12/4/2009)... Leskovar, a Texas AgriLife Research plant physiol... Center in Uvalde, has been investigating ways to ...tion from the greenhouse to the field. , "This r...ossibly even the further profitability of some veg...ive plants that will establish well," Leskovar sai...
(Date:12/4/2009)...vailable in German . , A new study of the Max... to understand the positive effect of dietary rest...different organisms (fruit flies and mice) have sh...but with a potential negative side effect of dimin...s less frequently with a reduced litter size on a ...
(Date:12/3/2009)...earn new information and adapt to changes in our d...mories, appears to lie in the minute junctions whe...dy by NYU Langone Medicine Center researchers. The...l Nature . , The scientists, led by Wen-Biao G...roscience at NYU School of Medicine, discovered th...
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4How nutrition affects healthy aging 2Lifelong memories linked to stable nerve connections 2Dr James OConnell Named J H Kanter Prize Laureate 54148 1Dr James OConnell Named J H Kanter Prize Laureate 54148 2Dr James OConnell Named J H Kanter Prize Laureate 54148 3Kevin Nealon Jordan Farmar Walter Perez Cristian de la Fuente and Other Celebrities Participated in Beach Volleyball Match for Children With Cancer 54145 1Kevin Nealon Jordan Farmar Walter Perez Cristian de la Fuente and Other Celebrities Participated in Beach Volleyball Match for Children With Cancer 54145 2Kevin Nealon Jordan Farmar Walter Perez Cristian de la Fuente and Other Celebrities Participated in Beach Volleyball Match for Children With Cancer 54145 3William Stanfield MD Is First Cleveland area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 13481 1William Stanfield MD Is First Cleveland area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 13481 2William Stanfield MD Is First Cleveland area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 13481 3William Stanfield MD Is First Cleveland area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 13481 4
...ne of the central challenges of our time is the su...ce-efficient energy to our society. In this contex...rtance. Bjrn Loges, Albert Boddien, Henrik Junge, ...talysis in Rostock have now succeeded in the contr...ut the need for the high-temperature reforming pro...
...ware, WALL, N.J., May 6 BIO-key International, I...-based biometric,identification and wireless publi...e showcasing its latest mobile data solution for B...forcement Information Management,(LEIM) Conference...t and,Convention Center in Nashville, TN., The LE...
...e exploited to make them more sensitive to heat an...School of Medicine in St. Louis report. , The Was...found that tumors have a built-in mechanism that p...ost likely decreases the benefit of hyperthermia a...ing with that protection, the researchers have sho...
Other Biology News:Power from formic acid 2BIO-key(R) Showcasing Public Safety Solutions for BlackBerry Smartphones at 2008 LEIM Conference 2BIO-key(R) Showcasing Public Safety Solutions for BlackBerry Smartphones at 2008 LEIM Conference 3Researchers find way to make tumor cells easier to destroy 2
... Clean-up Micro Kit provides a fast and simple pro...100 and other detergents from small samples of pro...sing Norgens patented protein resin as an ion exch... of either acidic or basic protein.A complete kit ...
...is critical to the maintenance of appropriate leve...tant and diverse as those involved in cellular met...resentation, modulation of cell surface receptors ...tion, and signalling factors. The ubiquitin-protea...
...ion Service includes 1. Scanning of gel(s) 2. Exci...yptic in-gel digestion and peptide extraction 4. P...of PMF (Peptide Mass Fingerprint) spectra via MALD...PFF (Peptide Fragmentation Fingerprint) spectra vi...
Yeast-GFP 96-well Plates from Invitrogen
Biology Products: